H00030 | |
H number | H00030 |
Name | Cervical cancer |
Description | Cervical cancer is the second largest cause of cancer-related death in women worldwide, and it occurs following persistent infection, sometimes for decades, with a specific subset of human papillomavirus (HPV) types, particularly types 16, 18, 33 and 42. Experimental studies show that the E6 and E7 genes of these high risk HPVs are oncogenes that deregulate key cell cycle controls. The E6 and E7 oncoproteins bind respectively to the p53 and Retinoblastoma (Rb) tumor suppressor proteins, which are involved in the regulation of growth control. The abnormalities in other cellular genes found in cervical cancer, including mutations in ras family of genes, and amplification in EGFR and ERBB2, may also play an important role in carcinogenesis and the aggressiveness of cervical tumors, although to date the role of most of these genetic abnormalities does not appear to be as important as the role of HPV. |
Category | Cancer |
Network | nt06166 Human papillomavirus (HPV) nt06511(H00030) NOTCH signaling nt06516(H00030) TNF signaling nt06517(H00030) TLR signaling nt06522(H00030) mTOR signaling nt06524(H00030) Apoptosis nt06526(H00030) MAPK signaling nt06530(H00030) PI3K signaling |
Gene | K-ras (mutation) [HSA:3845] [KO:K07827] H-ras (mutation) [HSA:3265] [KO:K02833] EGFR (amplification) [HSA:1956] [KO:K04361] ERBB2 (amplification) [HSA:2064] [KO:K05083] p21 (overexpression) [HSA:1026] [KO:K06625] CDK4 (overexpression) [HSA:1019] [KO:K02089] Bcl-2 (overexpression) [HSA:596] [KO:K02161] |
Pathogen | Human papillomavirus type 16 [GN:T40087] Human papillomavirus type 18 [GN:T40088] |
Env factor | - |
Carcinogen | - |
Drug | Recombinant adsorbed quadrivalent human papillomavirus virus-like particle vaccine [DR:D10192] Human papillomavirus 9-valent vaccine, recombinant [DR:D11863] Topotecan hydrochloride [DR:D02168] Pembrolizumab [DR:D10574] (PD-L1 expressed) Bevacizumab [DR:D06409] Tisotumab vedotin [DR:D11814] |
Comment | - |
Other DBs | ICD-11: 2C77 ICD-10: C53 MeSH: D002583 |
Reference | PMID:11486705 AUTHORS Wolf JK, Ramirez PT. TITLE The molecular biology of cervical cancer. JOURNAL Cancer Invest 19:621-9 (2001) DOI:10.1081/CNV-100104290 PMID:10471054 AUTHORS Lazo PA. TITLE The molecular genetics of cervical carcinoma. JOURNAL Br J Cancer 80:2008-18 (1999) DOI:10.1038/sj.bjc.6690635 PMID:16062089 AUTHORS Patel P, Moazzam N, Potti A, Mehdi SA. TITLE Azathioprine induced hodgkin lymphoma: a case report and review of literature. JOURNAL Am J Clin Oncol 28:427-8 (2005) DOI:10.1097/01.coc.0000168670.28659.8d PMID:15168959 AUTHORS Schrager S, Potter BE. TITLE Diethylstilbestrol exposure. JOURNAL Am Fam Physician 69:2395-400 (2004) PMID:17390375 AUTHORS Troisi R, Hatch EE, Titus-Ernstoff L, Hyer M, Palmer JR, Robboy SJ, Strohsnitter WC, Kaufman R, Herbst AL, Hoover RN. TITLE Cancer risk in women prenatally exposed to diethylstilbestrol. JOURNAL Int J Cancer 121:356-60 (2007) DOI:10.1002/ijc.22631 PMID:11281434 AUTHORS Severson J, Evans TY, Lee P, Chan T, Arany I, Tyring SK. TITLE Human papillomavirus infections: epidemiology, pathogenesis, and therapy. JOURNAL J Cutan Med Surg 5:43-60 (2001) DOI:10.1177/120347540100500110 PMID:15489140 AUTHORS Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA. TITLE Environmental and chemical carcinogenesis. JOURNAL Semin Cancer Biol 14:473-86 (2004) DOI:10.1016/j.semcancer.2004.06.010 PMID:15552776 AUTHORS Sasco AJ, Secretan MB, Straif K. TITLE Tobacco smoking and cancer: a brief review of recent epidemiological evidence. JOURNAL Lung Cancer 45 Suppl 2:S3-9 (2004) DOI:10.1016/j.lungcan.2004.07.998 PMID:12612656 AUTHORS Baldwin P, Laskey R, Coleman N. TITLE Translational approaches to improving cervical screening. JOURNAL Nat Rev Cancer 3:217-26 (2003) DOI:10.1038/nrc1010 PMID:12797857 AUTHORS Garland SM. TITLE Can we really beat cervical cancer? JOURNAL Med J Aust 178:647-9 (2003) DOI:10.5694/j.1326-5377.2003.tb05396.x PMID:14739059 AUTHORS Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR. TITLE Serum tumor markers in the management of ovarian, endometrial and cervical cancer. JOURNAL Biomed Pharmacother 58:24-38 (2004) DOI:10.1016/j.biopha.2003.11.003 |